<DOC>
	<DOCNO>NCT00239681</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness long-term therapy rosuvastatin compare placebo , evaluate whether treatment rosuvastatin might effective reduce risk major cardiovascular event .</brief_summary>
	<brief_title>JUPITER - Crestor 20mg Versus Placebo Prevention Cardiovascular ( CV ) Events</brief_title>
	<detailed_description>AstraZeneca announce decide stop CRESTOR JUPITER clinical study early base recommendation Independent Data Monitoring Board JUPITER Steering Committee , meet March 29 , 2008 . The study stop early unequivocal evidence reduction cardiovascular morbidity mortality amongst patient receive CRESTOR compare placebo .</detailed_description>
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<criteria>Men 50 year old , woman 60 year older Low normal level low density lipoprotein ( LDL ) cholesterol ( &lt; 130mg/dL ) Elevated level CReactive Protein ( CRP ) &gt; 2.0 mg/L History cardiovascular cerebrovascular event Active liver disease Diabetes mellitus Uncontrolled hypertension hypothyroidism History certain malignancy Chronic inflammatory condition History alcohol drug abuse</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Primary prevention</keyword>
	<keyword>Cardiovascular disease</keyword>
	<keyword>Statin therapy</keyword>
	<keyword>C-reactive protein</keyword>
</DOC>